Atara Biotherapeutics, Inc. 8-K

What Happened
Atara Biotherapeutics, Inc. (ATRA) filed a Form 8-K on January 12, 2026 (Items 2.02 and 8.01) to announce a preliminary estimate of its cash, cash equivalents and short-term investments as of December 31, 2025. The company disclosed the information via a press release dated January 12, 2026 (filed as Exhibit 99.1). The filing states this is a preliminary estimate based on currently available information and does not present all information necessary for a complete understanding of Atara’s financial condition as of December 31, 2025 or its results of operations for the quarter ended that date.

Key Details

• The disclosure was made in a press release dated January 12, 2026 (Exhibit 99.1 to the Form 8-K).
• The announcement reported Atara’s cash, cash equivalents and short-term investments as of December 31, 2025 (the filing does not include additional financial details beyond the press release).
• The company characterized the figure as a preliminary estimate and warned it may not reflect all information needed to fully assess year‑end financial condition or fourth-quarter results.
• The filing also includes the interactive XBRL cover page (Exhibit 104).

Why It Matters
Liquidity (cash and short-term investments) is a key metric for investors assessing a biotech company’s ability to fund operations, development programs, and potential milestones without near-term financing. Because Atara labeled the figure preliminary and said the 8-K does not present all necessary information for a full understanding of year‑end results, investors should review the attached press release (Exhibit 99.1) and await the company’s complete fourth-quarter and year-end filings for finalized numbers and additional context.